Dynavax Technologies Corp (NASDAQ:DVAX)

Data as of Sep 15
 -0.03 / -2.13%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Its lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. The company's other products under pipeline are DV1179 (TLR Inhibitor for Lupus) and AZD1419 (Asthma Therapy). Dynavax Technologies was founded by Lawrence M. Lichtenstein, Dennis A. Carson and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Contact Information

Dynavax Technologies Corp.
2929 7th Street
Berkeley California 94710-2753
P:(510) 848-5100
Investor Relations:



Individual stakeholders6.40%
Mutual fund holders37.29%
Other institutional29.50%

Top Executives

Eddie J. GrayChief Executive Officer & Director
David F. NovackSenior Vice President-Operations & Quality
Michael S. OstrachCFO, Secretary, Chief Business Officer & VP
Robert L. CoffmanChief Scientific Officer & Senior Vice President
Robert JanssenChief Medical Officer & VP-Regulatory Affairs

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.